What is the current valuation of the US obstructive lung-disease market?

The market valuation was $6.58 Billion in 2024. Read More

What is the projected market size for the US obstructive lung-disease market by 2035?

The market is expected to reach $11.39 Billion by 2035. Read More

What is the expected CAGR for the US obstructive lung-disease market during the forecast period 2025 - 2035?

The expected CAGR is 5.12% during the forecast period. Read More

Which segment is projected to have the highest valuation in the US obstructive lung-disease market?

Chronic Obstructive Pulmonary Disease (COPD) is projected to reach $5.0 Billion by 2035. Read More

What are the key product types in the US obstructive lung-disease market?

Inhalers and nebulizers are key product types, with inhalers projected to reach $5.66 Billion by 2035. Read More

Which drug class is expected to show significant growth in the US obstructive lung-disease market?

Combination drugs are expected to grow to $2.5 Billion by 2035. Read More

What is the anticipated market size for hospitals and diagnostic centers as end-users in the US obstructive lung-disease market?

Hospitals and diagnostic centers are projected to reach $3.5 Billion by 2035. Read More

Who are the leading companies in the US obstructive lung-disease market?

Key players include GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca. Read More

What is the expected growth for the bronchiectasis segment in the US obstructive lung-disease market?

The bronchiectasis segment is projected to grow to $1.2 Billion by 2035. Read More

How does the market for inhaled corticosteroids compare to other drug classes in the US obstructive lung-disease market?

Inhaled corticosteroids are expected to reach $2.0 Billion by 2035, indicating strong demand. Read More

US Obstructive Lung Disease Market

ID: MRFR/Pharma/15193-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Obstructive Lung Disease Market Research Report By Disease Type (Asthma, Bronchitis, Copd) and By Product Type (Inhalers, Nebulizers) - Growth & Industry Forecast 2025 To 2035

US Obstructive Lung Disease Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Billion)
  1. 4.1.1 Asthma
  2. 4.1.2 Bronchiectasis
  3. 4.1.3 Bronchitis
  4. 4.1.4 Chronic Obstructive Pulmonary Disease (COPD)
  5. 4.1.5 Others
2. 4.2 Pharmaceutical, BY Product Type (USD Billion)
  1. 4.2.1 Inhalers
  2. 4.2.2 Nebulizers
  3. 4.2.3 Others
3. 4.3 Pharmaceutical, BY Drug Class (USD Billion)
  1. 4.3.1 Combination Drugs
  2. 4.3.2 Leukotriene Antagonists (LTA)
  3. 4.3.3 Inhaled Corticosteroids (ICS)
  4. 4.3.4 Anticholinergics
  5. 4.3.5 Short Acting Beta Agonists (SABA)
  6. 4.3.6 Long Acting Beta Agonists (LABA)
  7. 4.3.7 Others
4. 4.4 Pharmaceutical, BY Route of Administration (USD Billion)
  1. 4.4.1 Oral
  2. 4.4.2 Inhaler
  3. 4.4.3 Intravenous
  4. 4.4.4 Subcutaneous
  5. 4.4.5 Others
5. 4.5 Pharmaceutical, BY End-User (USD Billion)
  1. 4.5.1 Hospitals & Diagnostic Centers
  2. 4.5.2 Academic Institutes
  3. 4.5.3 Pharmaceutical & Biotechnology Companies
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva Pharmaceutical Industries (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Mylan (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY PRODUCT TYPE
4. 6.4 US MARKET ANALYSIS BY DRUG CLASS
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY END-USER
7. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF PHARMACEUTICAL
10. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
12. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Billion)
15. 6.15 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
16. 6.16 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
17. 6.17 PHARMACEUTICAL, BY DRUG CLASS, 2024 (% SHARE)
18. 6.18 PHARMACEUTICAL, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
19. 6.19 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
20. 6.20 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
21. 6.21 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
22. 6.22 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  5. 7.2.5 BY END-USER, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Billion, 2025-2035)

Asthma
Bronchiectasis
Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)
Others

Pharmaceutical By Product Type (USD Billion, 2025-2035)

Inhalers
Nebulizers
Others

Pharmaceutical By Drug Class (USD Billion, 2025-2035)

Combination Drugs
Leukotriene Antagonists (LTA)
Inhaled Corticosteroids (ICS)
Anticholinergics
Short Acting Beta Agonists (SABA)
Long Acting Beta Agonists (LABA)
Others

Pharmaceutical By Route of Administration (USD Billion, 2025-2035)

Oral
Inhaler
Intravenous
Subcutaneous
Others

Pharmaceutical By End-User (USD Billion, 2025-2035)

Hospitals & Diagnostic Centers
Academic Institutes
Pharmaceutical & Biotechnology Companies
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”